Brinda Emu, MD
DownloadHi-Res Photo
Cards
Appointments
Infectious Diseases
Primary
Pathology
Secondary
Titles
Director, Cancer-ID Clinic, Internal Medicine; co-Leader, Cancer Microbiology Working Group, Yale Cancer Center
Contact Info
Appointments
Infectious Diseases
Primary
Pathology
Secondary
Titles
Director, Cancer-ID Clinic, Internal Medicine; co-Leader, Cancer Microbiology Working Group, Yale Cancer Center
Contact Info
Appointments
Infectious Diseases
Primary
Pathology
Secondary
Titles
Director, Cancer-ID Clinic, Internal Medicine; co-Leader, Cancer Microbiology Working Group, Yale Cancer Center
Contact Info
About
Titles
Associate Professor of Medicine (Infectious Diseases)
Director, Cancer-ID Clinic, Internal Medicine; co-Leader, Cancer Microbiology Working Group, Yale Cancer CenterBiography
Dr. Emu received her B.A. from Harvard University and her M.D. from Johns Hopkins University School of Medicine. She completed an Internal Medicine residency at Beth Israel Deaconess Medical Center and fellowship in Infectious Diseases at the University of California, San Francisco. She remained on faculty at UCSF from 2004 to 2009, studying immune correlates of protection in HIV-infected individuals. Dr Emu then worked as Medical Director in early clinical development at Genentech, Inc in South San Francisco (2009-2012). While at Genentech, she focused on development of novel therapeutic approaches to unmet needs in infectious diseases, inflammation, and oncology.
Dr. Emu joined the Division of Infectious Diseases at Yale School of Medicine in 2013. Her laboratory studies the intersection of chronic viral infection and oncology, with a focus on HIV-associated malignancies. Specifically, she studies the impact of HIV-associated immune dysfunction on carcinogenesis and tumor progression.
Appointments
Infectious Diseases
Associate Professor on TermPrimaryPathology
Associate Professor on TermSecondary
Other Departments & Organizations
- AIDS Care Program
- Cancer Immunology
- Cancer-Infectious Diseases (Cancer-ID) Program
- Infectious Diseases
- Internal Medicine
- Pathology
- Yale Medicine
- Yale Ventures
- Yale-UPR Integrated HIV Basic and Clinical Sciences Initiative
Education & Training
- Residency
- Beth Israel Deaconess Medical Center (2001)
- MD
- Johns Hopkins University School of Medicine (1998)
- AB
- Harvard University (1994)
Research
Overview
- Evaluation of different T cell phenotypes/function across different ages of HIV-infected indivdiuals on antiretroviral therapy, compared with HIV-uninfected individuals
- Impact of T cell aberrancies on incidence of cancer in the setting of chronic viral infection
- Evaluating immunologic parameters of individuals with cancer diagnoses in setting of HIV infection
Medical Subject Headings (MeSH)
Head and Neck Neoplasms; Hematologic Neoplasms; HIV; Immune Evasion; Immune Reconstitution; Immune System; Immunocompromised Host; Infectious Disease Medicine; Lymphoma; Thoracic Neoplasms; T-Lymphocytes
Research at a Glance
Yale Co-Authors
Frequent collaborators of Brinda Emu's published research.
Publications Timeline
A big-picture view of Brinda Emu's research output by year.
Research Interests
Research topics Brinda Emu is interested in exploring.
Amy Justice, MD, PhD
Geliang Gan, MPH, PhD
Kurt Schalper, MD, PhD
Albert C Shaw, MD, PhD
Lydia Aoun-Barakat, MD
Saral Mehra, MD, MBA, FACS
37Publications
3,040Citations
HIV
T-Lymphocytes
Head and Neck Neoplasms
Publications
Featured Publications
Human Immunodeficiency Virus Is Associated With Poor Overall Survival Among Patients With Head and Neck Cancer
Salahuddin S, Cohen O, Wu M, Irizarry J, Vega T, Gan G, Deng Y, Isaeva N, Prasad M, Schalper K, Mehra S, Yarbrough W, Emu B. Human Immunodeficiency Virus Is Associated With Poor Overall Survival Among Patients With Head and Neck Cancer. Clinical Infectious Diseases 2022, 76: 1449-1458. PMID: 36520995, PMCID: PMC10319962, DOI: 10.1093/cid/ciac924.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsOverall survivalIndependent predictorsHNSCC patientsWorse prognosisOropharyngeal tumorsCox proportional hazards regression modelMultivariate analysisHPV-positive oropharyngeal tumorsNeck squamous cell cancerProportional hazards regression modelsLower median overall survivalAcademic hospital centerNon-HIV populationMedian overall survivalPredictors of survivalSquamous cell cancerHuman immunodeficiency virusPoor clinical outcomeExpression of CD4Poor overall survivalHazards regression modelsRace/ethnicityCD8 infiltrationHazard ratioClinicopathologic characteristicsPatients with HIV-associated cancers have evidence of increased T cell dysfunction and exhaustion prior to cancer diagnosis
Chaudhary O, Trotta D, Wang K, Wang X, Chu X, Bradley C, Okulicz J, Maves RC, Kronmann K, Schofield CM, Blaylock JM, Deng Y, Schalper KA, Kaech SM, Agan B, Ganesan A, Emu B. Patients with HIV-associated cancers have evidence of increased T cell dysfunction and exhaustion prior to cancer diagnosis. Journal For ImmunoTherapy Of Cancer 2022, 10: e004564. PMID: 35470232, PMCID: PMC9039380, DOI: 10.1136/jitc-2022-004564.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsViral suppressionTraditional risk factorsCase-control study designMarker of riskControl study designHIV infectionStudy cohortInhibitory receptorsRisk factorsCancer casesT cellsStudy designCancer diagnosisPLWHHIVCancerRiskCD4CellsPatientsTranscription factorsClinical cancer diagnosisCohortSuppressionInfectionCancer Microbiology
DiMaio D, Emu B, Goodman AL, Mothes W, Justice A. Cancer Microbiology. Journal Of The National Cancer Institute 2021, 114: 651-663. PMID: 34850062, PMCID: PMC9086797, DOI: 10.1093/jnci/djab212.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsDirect carcinogenic effectSpecific immune interactionsMiddle-income countriesCancer controlCancer preventionInfection controlImmune interactionsCancerCancer treatmentCarcinogenic effectsExposure reductionDrug developmentCancer formationPublic healthTreatmentHuman microbiomeCross-disciplinary trainingVaccineAntiviralsPreventionImportant roleUptake of oxidized lipids by the scavenger receptor CD36 promotes lipid peroxidation and dysfunction in CD8+ T cells in tumors
Xu S, Chaudhary O, Rodríguez-Morales P, Sun X, Chen D, Zappasodi R, Xu Z, Pinto AFM, Williams A, Schulze I, Farsakoglu Y, Varanasi SK, Low JS, Tang W, Wang H, McDonald B, Tripple V, Downes M, Evans RM, Abumrad NA, Merghoub T, Wolchok JD, Shokhirev MN, Ho PC, Witztum JL, Emu B, Cui G, Kaech SM. Uptake of oxidized lipids by the scavenger receptor CD36 promotes lipid peroxidation and dysfunction in CD8+ T cells in tumors. Immunity 2021, 54: 1561-1577.e7. PMID: 34102100, PMCID: PMC9273026, DOI: 10.1016/j.immuni.2021.05.003.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsTumor microenvironmentCell dysfunctionLipid peroxidationLipid accumulationOxidized low-density lipoproteinExpression of CD36Low-density lipoproteinCommon metabolic alterationsScavenger receptor CD36Intratumoral CD8Immune dysfunctionEffector TGlutathione peroxidase 4CD8Effector functionsInhibition of p38Metabolic alterationsReceptor CD36Therapeutic avenuesScavenger receptorsDysfunctionWT counterpartsTILsCell functionCD36Decreased Overall Survival in HIV-associated Non–small-cell Lung Cancer
Hysell K, Yusuf R, Barakat L, Virata M, Gan G, Deng Y, Perez-Irizarry J, Vega T, Goldberg SB, Emu B. Decreased Overall Survival in HIV-associated Non–small-cell Lung Cancer. Clinical Lung Cancer 2020, 22: e498-e505. PMID: 33468393, PMCID: PMC8169710, DOI: 10.1016/j.cllc.2020.11.006.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsCell lung cancerGeneral patientsNSCLC populationLung cancerCox proportional hazards modelYale-New Haven HospitalGeneral NSCLC populationOutcomes of patientsOverall median survivalRetrospective cohort studyPredictors of survivalKaplan-Meier curvesHIV-1 RNACopies/mLLog-rank testProportional hazards modelNew Haven HospitalCancer treatment regimensMedian CD4Antiretroviral therapyCohort studyMedian survivalOverall survivalHIV infectionMedian age661. Ibalizumab Efficacy and Safety Through 48 Weeks of Treatment: Results of an Expanded Access Protocol (TMB-311)
Emu B, DeJesus E, Berhe M, Leider J, Creticos C, Weinheimer S, Cohen Z. 661. Ibalizumab Efficacy and Safety Through 48 Weeks of Treatment: Results of an Expanded Access Protocol (TMB-311). Open Forum Infectious Diseases 2019, 6: s303-s303. PMCID: PMC6811265, DOI: 10.1093/ofid/ofz360.729.Peer-Reviewed Original ResearchCitationsConceptsTreatment-emergent adverse eventsWeeks of treatmentCopies/mLViral loadCopies/Cohort 2Multidrug-resistant HIV-1 infectionDay 0HIV-1 RNA levelsImmune reconstitution inflammatory syndromeLog10 copies/mLHIV-1 viral loadPivotal phase 3 studiesCohort 2 patientsDurable viral suppressionMajor eligibility criteriaReconstitution inflammatory syndromeWeek 24 visitCD4 cell countMedian viral loadTreatment-experienced patientsCells/mm3Phase 3 studyInjection site reactionsLog10 copies/437 Safety and efficacy of immune checkpoint inhibitors (ICI) in patients living with HIV (PLWH) and metastatic non-small cell lung cancer (NSCLC): a matched cohort study from the international CATCH-IT consortium
Zarif T, Nassar A, Adib E, Fitzgerald B, Huang J, Mouhieddine T, Nonato T, McKay R, Li M, Mittra A, Owen D, Lorentsen M, Dittus C, Dizman N, Emu B, Falohun A, Abdel-Wahab N, Bankapur A, Reed A, Dobbs R, Kim C, Arora A, Shah N, El-Am E, Kozaily E, Abdallah W, Al-Hader A, Ghazal B, Saeed A, Drolen C, Lechner M, Espinar J, Nebhan C, Johnson D, Haykal T, Morse M, Cortellini A, Pinato D, Pria A, Bower M, Hall E, Bakalov V, Bahary N, Rajkumar A, Mangla A, Shah V, Singh P, Nana F, Lia N, Dima D, Funchain P, Saleem R, Woodford R, Long AO G, Menzies A, Genova C, Barletta G, Puri S, Florou V, Idossa D, Queirolo P, Lamberti G, Addeo A, Bersanelli M, Freeman D, Xie W, Ramaswami R, Marron T, Choueiri T, Lurain K, Baden L, Sonpavde G, Naqash A. 437 Safety and efficacy of immune checkpoint inhibitors (ICI) in patients living with HIV (PLWH) and metastatic non-small cell lung cancer (NSCLC): a matched cohort study from the international CATCH-IT consortium. 2022, a457-a458. DOI: 10.1136/jitc-2022-sitc2022.0437.Peer-Reviewed Original ResearchCitations
2023
1014 Adrenergic receptors regulate T cell differentiation in viral infection and cancer
Globig A, Zhao S, Roginsky J, Avina-Ochoa N, Heeg M, Chaudhary O, Hoffmann F, Chen D, O’Connor C, Emu B, Kaech S. 1014 Adrenergic receptors regulate T cell differentiation in viral infection and cancer. 2023, a1122-a1122. DOI: 10.1136/jitc-2023-sitc2023.1014.Peer-Reviewed Original ResearchSafety and Activity of Immune Checkpoint Inhibitors in People Living With HIV and Cancer: A Real-World Report From the Cancer Therapy Using Checkpoint Inhibitors in People Living With HIV-International (CATCH-IT) Consortium
El Zarif T, Nassar A, Adib E, Fitzgerald B, Huang J, Mouhieddine T, Rubinstein P, Nonato T, McKay R, Li M, Mittra A, Owen D, Baiocchi R, Lorentsen M, Dittus C, Dizman N, Falohun A, Abdel-Wahab N, Diab A, Bankapur A, Reed A, Kim C, Arora A, Shah N, El-Am E, Kozaily E, Abdallah W, Al-Hader A, Abu Ghazal B, Saeed A, Drolen C, Lechner M, Drakaki A, Baena J, Nebhan C, Haykal T, Morse M, Cortellini A, Pinato D, Dalla Pria A, Hall E, Bakalov V, Bahary N, Rajkumar A, Mangla A, Shah V, Singh P, Aboubakar Nana F, Lopetegui-Lia N, Dima D, Dobbs R, Funchain P, Saleem R, Woodford R, Long G, Menzies A, Genova C, Barletta G, Puri S, Florou V, Idossa D, Saponara M, Queirolo P, Lamberti G, Addeo A, Bersanelli M, Freeman D, Xie W, Reid E, Chiao E, Sharon E, Johnson D, Ramaswami R, Bower M, Emu B, Marron T, Choueiri T, Baden L, Lurain K, Sonpavde G, Naqash A. Safety and Activity of Immune Checkpoint Inhibitors in People Living With HIV and Cancer: A Real-World Report From the Cancer Therapy Using Checkpoint Inhibitors in People Living With HIV-International (CATCH-IT) Consortium. Journal Of Clinical Oncology 2023, 41: 3712-3723. PMID: 37192435, PMCID: PMC10351941, DOI: 10.1200/jco.22.02459.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsImmune-related adverse eventsProgression-free survivalObjective response rateOverall survivalMetastatic NSCLCCheckpoint inhibitorsGrade immune-related adverse eventsImmune checkpoint inhibitor trialsNeck squamous cell carcinomaActivity of ICICheckpoint inhibitor trialsCohort of PWHImmune checkpoint inhibitorsHIV viral loadKaplan-Meier methodSquamous cell carcinomaUse of ICIMean survival timeMost common cancersL1 monotherapyRECIST 1.1Adverse eventsInhibitor trialsMedian ageAdvanced cancerBuilding an Infectious Disease Diversity, Equity, and Antiracism (ID2EA) Curriculum: A Single Center's Experience and Reflections
Gleeson S, Zapata H, Bathgate M, Emu B, Frederick J, Friedland G, Golden M, Meyer J, Radin J, Sideleau R, Shaw A, Shenoi S, Trubin P, Virata M, Barakat L, Desruisseaux M. Building an Infectious Disease Diversity, Equity, and Antiracism (ID2EA) Curriculum: A Single Center's Experience and Reflections. Clinical Infectious Diseases 2023, 77: 703-710. PMID: 37078888, DOI: 10.1093/cid/ciad236.Peer-Reviewed Original ResearchAltmetricMeSH Keywords and ConceptsConceptsEducational activitiesHealthcare inequitiesInfectious Diseases SectionSingle-center experienceCoronavirus disease 2019 (COVID-19) pandemicDisease 2019 pandemicMixed-methods assessmentLearning objectivesPilot curriculumEducational trainingCurriculumCenter experienceLong-term behavioral changesProgram outcomesDisease sectionDisease diversityPhysician perspectivesResponse rateHealth disparitiesYale SchoolInequitiesAntiracismBehavioral changesRacismEquity
Clinical Trials
Current Trials
Mechanisms of HIV latency
HIC ID2000021845REGRoleSub InvestigatorPrimary Completion Date12/31/2048Recruiting ParticipantsGenderBothAge18+ years
Academic Achievements and Community Involvement
activity Member
Professional OrganizationsAIDS Clinical Trials GroupDetails11/01/2018 - PresentDescriptionElected Member of the Inflammation Transformative Science Group
Clinical Care
Overview
Clinical Specialties
Infectious Diseases
Fact Sheets
Parasitic Diseases
Learn More on Yale MedicineGastroenteritis
Learn More on Yale MedicineHuman Immunodeficiency Virus (HIV)
Learn More on Yale MedicineSepsis
Learn More on Yale Medicine
Board Certifications
Infectious Disease
- Certification Organization
- AB of Internal Medicine
- Latest Certification Date
- 2015
- Original Certification Date
- 2005
Yale Medicine News
Are You a Patient?
View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.
View Doctor ProfileLinks & Media
News
- January 30, 2024
Fostering Equity and Inclusion in Infectious Diseases at Yale
- November 02, 2023
Offering Specialized Care & Research For Patients with Cancer and HIV
- March 21, 2023
Department of Internal Medicine Promotions and Reappointments
- November 01, 2022
HIV and Cancer: Meeting a Need
Related Links
Get In Touch
Contacts
Email
Appointment Number
Locations
Patient Care Locations
Are You a Patient? View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.
Administrative Support